Who is sponsoring NCT03943446?

NCT03943446 is sponsored by Takeda.

What condition does NCT03943446 study?

NCT03943446 studies Crohn Disease.

What drugs are being tested in NCT03943446?

Interventions: TAK-018, TAK-018 Placebo.

What is the status of NCT03943446?

NCT03943446 is currently TERMINATED.

Last reviewed 2023-09-07 · How we verify

A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery

NCT03943446 PHASE2 TERMINATED Results posted

The main aim is to see if TAK-018 reduces the recurrence of intestinal inflammation after abdominal resection surgery in adults with Crohn's disease. Participants will take either TAK-018 or placebo tablets by mouth, 2 times each day for up to 26 weeks after surgery. The placebo looks like TAK-018 but will not have any medicine in it. Participants will have 6 study visits while receiving treatment. Visits 1 and 6 will be conducted at the study clinic. The others can be in the clinic or at the participant's home. Follow-up will occur 4 weeks after final treatment.

Details

Lead sponsor	Takeda
Phase	PHASE2
Status	TERMINATED
Enrolment	34
Start date	Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Aug 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Crohn Disease

Interventions

TAK-018
TAK-018 Placebo

Countries

France, Austria, United Kingdom, Germany, United States